|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||131.41 - 133.58|
|52 Week Range||121.00 - 148.99|
|Beta (3Y Monthly)||0.76|
|PE Ratio (TTM)||21.90|
|Earnings Date||Oct 15, 2019|
|Forward Dividend & Yield||3.80 (2.87%)|
|1y Target Est||149.28|
JNJ earnings report could be a boon for medical stocks Boston Scientific and Penumbra, an analyst said Wednesday. Boston has efforts in electrophysiology. Penumbra works in stroke treatment.
FlexShares, a major purveyor of smart beta exchange traded funds, is throwing its weight around in the low volatility ETF arena in a big way with the introduction of three funds that combine that investment ...
Johnson & Johnson (NYSE: JNJ) shares are down 2% since the company reported a second-quarter earnings beat on Tuesday morning. Johnson & Johnson reported a 42% increase in net profit in the quarter. The company also reiterated its full-year earnings guidance and raised its sales forecast, but investors seem increasingly concerned about the potential negative impacts of opioid and talc litigation.
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
The World Health Organization has declared an international emergency over the Ebola epidemic in the Democratic Republic of Congo, which has killed more than 1,600 people over the past year and shows no sign of declining. Dr Tedros Adhanom Ghebreyesus, WHO director-general, announced that the outbreak was now a “public health emergency of international concern” after a meeting of the UN-affiliated organisation’s emergency committee in Geneva. “We need to work together in solidarity with the DRC to end this outbreak,” said Dr Tedros.
Newly released federal data shows how drugmakers and distributors increased shipments of opioid painkillers across the U.S. as the nation’s addiction crisis accelerated from 2006 to 2012.
JNJ stock slipped Tuesday after Dow Jones component Johnson & Johnson topped Wall Street's second-quarter earnings and revenue forecasts, but kept its full-year profit guidance intact.
U.S. stocks edged lower on Tuesday as quarterly results from banks added to concerns about lower interest rates dampening their profits, while comments from U.S. President Donald Trump on trade also dragged down Wall Street's major indexes. Johnson & Johnson shares slipped 1.6% after the diversified healthcare company warned that competition from generic and copycat drugs could impact its third-quarter results.
With some marquee earnings reports out today, it would have been reasonable to expect some more action out of the major U.S. equity benchmarks. By the time the closing bell sounded, though, Tuesday had all the appearances of just another boring summertime trading day.Source: Shutterstock The Nasdaq Composite fell 0.43% while the S&P 500 gave up 0.34%. The Dow Jones Industrial Average was mostly flat, settling down 0.09%.Arguably adding to the disappointment that was Tuesday's broader market action was that there was some encouraging economic data out earlier in the day. Retail sales rose for a fourth consecutive month in June, indicating that one of the primary drivers of the U.S. economy, the consumer, remains sturdy. And that data point does not even include Amazon's (NASDAQ:AMZN) Prime Day, which shattered records.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip Prime Day spanned into today and some analysts forecast $5 billion or more in sales for Amazon, easily topping 2018's Prime Day haul of $3.2 billion. Bottom line: the consumer is in good health and that should be meaningful for riskier assets going forward.Now let's get into some of those earnings reports. Boffo BanksDow component JPMorgan Chase (NYSE:JPM), the largest U.S. bank, was one of the blue-chip index's standouts Tuesday, gaining 1.06%, after the company said it earned $2.59 a share on revenue of $29.57 billion. Analysts were expecting earnings of $2.51 per share and revenue of $28.9 billion.As was noted here yesterday, net interest margins could become problematic for banks if interest rates decline. To that end, JPMorgan pared its 2019 net interest margin guidance to $57.5 billion from $58 billion.Goldman Sachs (NYSE:GS) was another Dow leader today, adding 1.87% after the investment bank said it earned $5.81 a share on revenue of $9.46 billion. Analysts expected earnings of $4.89 per share on revenue of $8.83 billion."Institutional client revenue, which includes trading, slipped 3%, while investment banking revenue was down 9%. However, revenue from the bank's investing and lending business rose 16%, its highest quarterly performance in eight years," according to Reuters. A Beat, but DisappointmentPharmaceuticals giant Johnson & Johnson (NYSE:JNJ) slipped 1.64% despite delivering an upbeat second-quarter report. The healthcare company said it earned $2.58 per share on sales of $20.56 billion. Wall Street expected a profit of $2.46 per share on sales of $20.29 billion.More importantly, JNJ boosted its 2019 sales forecast, excluding currency movement, to $82.4 billion to $83.2 billion, from an original range of $82 billion to $82.8 billion and the stock still declined. Credit Suisse resumed coverage of JNJ today with a $156 price target, implying significant upside from current levels. Quick AsideOnce again, Dow Inc (NYSE:DOW) was one of the Dow's best performers today, surging 2.73%. The stock has been on a torrid pace as of late. Investors considering the chemical maker may want to go here to mull over some of the bullish catalysts for the name. Bottom LineToday's earnings reports were mostly solid. It's certainly hard to quibble with JNJ raising revenue guidance, but plenty of tests remain this week and trade is clearly still an issue. President Donald Trump confirmed as much, noting the U.S. and China still have a long way to go on trade.Thursday is potentially significant day on the earnings front with Microsoft (NASDAQ:MSFT) and UnitedHealth (NYSE:UNH) among the Dow components reporting. Investors looking for a particular factor to watch should consider profit margins, regardless of company or sector."Many investors and analysts say a potential decline in profit margins--a measurement of how much a company's sales exceed its costs--is more worrisome than contracting earnings in the second quarter," according to the Wall Street Journal.Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading The post Dow Jones Today: Earnings Disappointments appeared first on InvestorPlace.
(Bloomberg) -- Johnson & Johnson raised its revenue guidance for the year, as strong sales in its pharmaceutical unit helped cushion a decline in the consumer and medical technology businesses.Second-quarter adjusted earnings were $2.58 a share, topping the $2.45 average of analysts’ estimates. To read more details on the results, click here.Key InsightsThe company’s full revenue is actually down from a year prior. Part of that can be attributed to the company’s divestiture of its medical sterilization business, ASP, which it sold to Fortive Corp. earlier this year. The company was also hit badly by foreign exchange rates. Almost half of J&J’s sales come from outside the U.S., and its fastest-growing segment -- overseas pharmaceuticals -- had its growth cut nearly in half because of currency fluctuations.J&J’s drug business is the largest of the company’s three main segments and accounts for more than half of all revenue. Its cancer drugs, including Darzalex and Imbruvica, drove growth in the quarter and were up 9.8% from a year prior.Market ReactionThe shares were down 1% to $133.41 at 9:43 a.m. in New York. The stock is up 4.4% this year to date as of Monday’s close, trailing the broader market.(Corrects spelling of cancer drug Darzalex in “Key Insights” section.)To contact the reporter on this story: Riley Griffin in New York at email@example.comTo contact the editor responsible for this story: Drew Armstrong at firstname.lastname@example.orgFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Shares of Johnson & Johnson fell Tuesday afternoon, despite the company reporting second-quarter earnings and revenue that soundly beat Wall Street expectations.
JNJ stock tried to break out in June. But several lawsuits claiming Johnson & Johnson baby powder caused cancer are weighing on shares. So, is the Dow Jones component a buy right now?
Johnson & Johnson earnings for the second quarter of 2019 have JNJ stock down on Tuesday.Source: Shutterstock Johnson & Johnson (NYSE:JNJ) reported earnings per share of $2.58 for the second quarter of the year. This is an increase over the company's earnings per share of $2.10 from the same time last year. It also beat out Wall Street's earnings per share estimate of $2.46 for the quarter, but couldn't keep JNJ stock from falling today.Net income reported in the Johnson & Johnson earnings report for the second quarter of 2019 comes in at $5.61 billion. This is up roughly 42% from the company's net income of $3.95 billion reported in the second quarter of the previous year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe Johnson & Johnson earnings report for the second quarter of the year has revenue coming in at $20.56 billion. This is a drop from the company's revenue of $20.83 billion reported in the same period of the year prior. Despite this, it still comes in above analysts' revenue estimate of $20.29 billion for the quarter, but JNJ stock is still falling on Tuesday.Johnson & Johnson also takes time in its most recent earnings report to update its 2019 guidance. This includes expecting its operational sales to increase between 3.2% and 3.7% from last year. However, the company doesn't increase its earnings per share estimate for the year even after beating estimates this quarter. * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip So what exactly is dragging JNJ stock down today? Concerns from the company about its large amount of lawsuits is one issue. Pressure from the government about its alleged role in the opioid crisis also isn't doing it any favors, either.JNJ stock was down 1% as of Tuesday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading As of this writing, William White did not hold a position in any of the aforementioned securities.The post Johnson & Johnson Earnings: JNJ Stock Dips Despite Q2 Beat, Raised Guidance appeared first on InvestorPlace.
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.
The Dow Jones industrials led the flattish stock market action early Tuesday. Goldman Sachs moved further above a buy point after its earnings release.